Denali Aims for $10M-$12M in Q3 as AVLAYAH Starts to Prove the Business Model

AVLAYAH's Q2 Start Makes the Q3 Target the Real Question

A modest beginning, then a much bigger guide

Denali now has one full quarter of AVLAYAH commercial sales, and that first full quarter produced $3.6 million in net product revenue. For a rare-disease launch, that is an early data point, not the main event. The more important number is management's projected third-quarter 2026 AVLAYAH net product revenue of $10 million to $12 million.

That is why the next report matters so much. Investors need to see whether this is the first real run rate for AVLAYAH or simply a soft opening that will slow as launch headwinds show through.

Why the $10M-$12M Step-Up Looks Plausible

First full quarter of commercial flow

AVLAYAH's first patients treated in the commercial setting in April means Q3 is the first full calendar quarter likely to reflect established treatment flow. In rare-disease launches, demand usually does not convert all at once; it takes time for referrals, prescribing habits, and payer workflows to settle.

By the end of Q2, Denali said commercial policies covered more than 50% of covered lives. That does not guarantee fast uptake, but it does suggest access is broad enough for revenue to grow if more covered patients move into treatment.

What needs to keep working

The clearest upside path is simpler access. Denali said it had reached roughly 80% of healthcare organizations treating eligible MPS II patients. If prior-authorization processing, appeals, and treatment starts improved through July and August, Q3 revenue could expand quickly because AVLAYAH is an ongoing therapy.

The risk is that launch momentum still depends on administrative friction clearing fast enough. In a small market, even modest delays in starting patients can keep revenue below guide.

AVLAYAH Proves Execution, but the Pipeline Still Drives the Bigger Story

Commercial proof and valuation

AVLAYAH gives Denali a commercial foundation and shows the TransportVehicle platform can move from concept to sold product. That matters, but mostly as proof that the company can execute beyond the lab.

The rest of the pipeline still matters more for valuation. Denali now has two Alzheimer's disease programs in clinical development, and that progress comes after the company received $195 million in gross proceeds from sale of a Priority Review Voucher, bringing pro forma cash, cash equivalents, and marketable securities to more than $1.1 billion. That balance sheet gives Denali time while AVLAYAH establishes the commercial base and the Alzheimer's programs move toward data.

The timing problem remains

Management also expects initial Alzheimer's data in 2027, so the next major value-changing evidence comes later. For now, AVLAYAH can support investor interest, but a larger re-rating likely depends on pipeline confirmation.

What Would Confirm or Challenge the Thesis

The balanced read is simple: Denali has earned attention, not blind trust. It already has a first full quarter of AVLAYAH commercial sales and has advanced two Alzheimer's programs into clinical development.

The main threshold

Treat the company's $10 million–$12 million in third-quarter revenue as the key confirmation point. If AVLAYAH reaches that range, investors can start to view the launch as an actual revenue curve rather than a promising start.

What to watch now

• Whether more covered patients actually move from policy coverage to treatment starts.
• Whether prior-authorization and reimbursement friction continues to ease.
• Whether pipeline timelines stay on the current schedule, keeping the next major data read in 2027.
• Whether Denali uses its cash position to accelerate both commercial and clinical progress.

Denali has built a credible early story. The next quarter should show how much of that story is already executing.